---
symbol: "LLY"
name: "Eli Lilly"
date: 2026-08-05
change_pct: 4.738198951017864
direction: "up"
event_type: "earnings"
url: "https://perplo.app/why/LLY/2026-08-05"
updated_at: 2026-08-05T11:06:50.685Z
---

# Why Eli Lilly (LLY) rose 4.74% on August 5, 2026

Eli Lilly (LLY) rose 4.74% on August 5, 2026 — Eli Lilly beats, raises 2026 outlook on GLP-1 surge.

## What happened

Eli Lilly beat consensus earnings, raised full-year 2026 revenue guidance, and reported surging Zepbound and Mounjaro sales across obesity and diabetes segments.

## Why it moved

Higher revenue guidance on proven demand for GLP-1 obesity/diabetes drugs re-rates Lilly's near-term growth and justifies margin expansion; strong execution dispels prior caution about supply constraints and adoption…

## Why it matters

A core driver of the GLP-1 / Obesity supercycle — Lilly's outsized beat and raised outlook validate the entire theme's durability after recent narrative weakness from Hims pressure and prior Lilly caution, reinforcing…

## What would break the thesis

If Rx growth decelerates in coming quarters or supply constraints re-emerge and cap the raised outlook, the move will be reversed as a false signal.

## Sources

- [Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge](https://www.cnbc.com/2026/08/05/eli-lilly-lly-earnings-q2-2026.html) — CNBC
- [Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started?](https://finnhub.io/api/news?id=4453440e15320b6c4f4fd1f510317ae6798277c904f1a88d29554629842e1dc7) — Yahoo
- [Eli Lilly to offer early access to next-gen obesity drug to some patients](https://www.investing.com/news/stock-market-news/eli-lilly-to-offer-early-access-to-nextgen-obesity-drug-to-some-patients-4832511) — Investing.com

---

Trade LLY perpetual futures 24/7 onchain: https://perplo.app/asset/LLY